← Human Trials & Peer-Reviewed Studies
Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis
Plain-language guide to PMID 20309523 (2011): controlled clinical trial study of Teriparatide in 20 women.
Key Facts
- PMID
- 20309523
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2011
- Study type
- Controlled Clinical Trial
- Authors
- Lasco A et al. (7 authors)
- DOI
- 10.1007/s00198-010-1222-5
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide, published as a controlled clinical trial.
The aim of their study was to investigate the effects of teriparatide on the hypophysis-adrenal axis in postmenopausal women.
The aim of their study was to investigate the effects of teriparatide on the hypophysis-adrenal axis in postmenopausal women.
Why It Was Studied
Teriparatide, recombinant human parathyroid hormone (1-34) (rhPTH [1-34]), is approved for the treatment of osteoporosis in men and postmenopausal women at high risk for fracture.
In literature, data regarding the secretagogue effect of PTH on adrenocortical cells are present on in vitro, but not on in vivo, studies.
Who Took Part
The abstract describes 20 women taking part.
By PubMed's age tags, the people studied were middle-aged adults, women only.
At the same time, 20 osteopenic women matched for age and body mass index with the patients were enrolled and treated only with calcium and vitamin D.
In all subjects, calcium, adrenocorticotropic hormone (ACTH), and plasmatic and urinary cortisol were evaluated at baseline and after 6 and 12 months.
What Was Measured
Topics PubMed links to this paper include Adrenocorticotropic Hormone, Bone Density Conservation Agents, Calcium, Hydrocortisone, Osteoporosis, Postmenopausal, Pituitary-Adrenal System and Teriparatide.
What This Means in Plain Language
This is a controlled clinical trial of Teriparatide in 20 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.